PT - JOURNAL ARTICLE AU - Fang, Chi AU - Tsai, Ching-Yi AU - Chien, Chih-Yen AU - Chan, Samuel H.H. TI - Causal contribution of malignancy to anomalous baroreflex functionality in patients with cancer: An overlooked aspect of cardio-oncology AID - 10.1101/2020.10.28.20221044 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.28.20221044 4099 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221044.short 4100 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221044.full AB - The current trend in cardio-oncology places major emphasis on circulatory toxicity induced by cancer therapy. Whether malignancy itself is a direct contributing factor to cardiovascular dysfunctions and baroreflex dysregulation in patients with cancer, however, has rarely appeared in literature. The present study addressed this largely overlooked aspect of cardio-oncology by evaluating blood pressure, heart rate and baroreflex functionality before and after curative surgery in patients with oral cavity squamous cell carcinoma (OSCC). We found that these patients exhibited reduced baroreflex-mediated sympathetic vasomotor tone and augmented cardiac vagal baroreflex, and such inherent anomalies were readily reversed to levels of healthy controls after surgical removal of the primary tumor. It is concluded that by being more prone to hypotension and bradycardia, anomalous baroreflex functionality causally induced by malignancy predisposes patients with cancer to detrimental cardiovascular abnormalities that may be further exacerbated by cancer therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported in part by the Chang Gung Medical Foundation, Taiwan (OMRPG8C0021) to S.H.H.C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval (104-6534B) was obtained from Chang Gung Medical Foundation, Taiwan.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReasonable requests for data referred to in the manuscript will be honored by communication with the corresponding author.